Avidity Biosciences: Funding, Investors & Team (Sep 2026)
Avidity Biosciences, Inc. is at the forefront of developing a novel class of therapies called AOCs that aim to address the limitations of current oligonucleotide treatments for various serious diseases. By utilizing its proprietary AOC platform, Avidity is able to create therapeutics that combine the tissue specifiUK monoclonal antibodies with the precision of oligonucleotide therapies, allowing for targeted treatment of previously inaccessible tissue and cell types as well as more effective targeting of the underlying genetic causes of diseases. Avidity's main product candidate, AOC 1001, is intended for the treatment of myotonic dystrophy type 1, with other programs focused on treating various muscle disorders such as muscle atrophy, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, and Pompe disease. In addition to muscle-related diseases, Avidity is also exploring the potential of its therapies in immune and other cell types.
Avidity Biosciences has raised $1.0B across 3 funding rounds on record, the most recent an undisclosed round of $345M announced in Aug 2024.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Avidity Biosciences Company Profile and Key Stats
Latest funding round on record: Aug 2024.
Avidity Biosciences Funding Rounds
Avidity Biosciences raised $207M in an undisclosed round announced in Dec 2022.
1.5 years later, an undisclosed round of $461M was announced in Jun 2024.
2 months later, an undisclosed round of $345M was announced in Aug 2024.
Avidity Biosciences Founders and Leadership Team
No contact details are on record for this team yet.
Avidity Biosciences Funding Compared to Other Biotechnology Startups
Avidity Biosciences' latest round of $345M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Avidity Biosciences in Biotechnology and San Diego
Companies Similar to Avidity Biosciences
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Avidity Biosciences Funding FAQs
What does Avidity Biosciences do?
Avidity Biosciences, Inc. is at the forefront of developing a novel class of therapies called AOCs that aim to address the limitations of current oligonucleotide treatments for various serious diseases. By utilizing its proprietary AOC platform, Avidity is able to create therapeutics that combine the tissue specifiUK monoclonal antibodies with the precision of oligonucleotide therapies, allowing for targeted treatment of previously inaccessible tissue and cell types as well as more effective targeting of the underlying genetic causes of diseases. Avidity's main product candidate, AOC 1001, is intended for the treatment of myotonic dystrophy type 1, with other programs focused on treating various muscle disorders such as muscle atrophy, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, and Pompe disease. In addition to muscle-related diseases, Avidity is also exploring the potential of its therapies in immune and other cell types.
How much funding has Avidity Biosciences raised?
Avidity Biosciences has raised $1.0B across 3 rounds on record. The most recent is an undisclosed round of $345M announced in Aug 2024.
When did Avidity Biosciences last raise funding?
Avidity Biosciences' most recent funding round on record is an undisclosed round of $345M, announced in Aug 2024.
Who founded Avidity Biosciences?
FundedIQ lists Mark E Davis (Founder), Mark E. Davis (Founder) at Avidity Biosciences.
Who is the CEO of Avidity Biosciences?
Sarah Boyce is listed as CEO at Avidity Biosciences.
Where is Avidity Biosciences headquartered?
Avidity Biosciences is based in San Diego, California, United States.
How many employees does Avidity Biosciences have?
Avidity Biosciences is in the 251-500 employee band.
How does Avidity Biosciences' funding compare to other Biotechnology startups?
Avidity Biosciences' latest round of $345M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Avidity Biosciences Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Avidity Biosciences is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.